Treatment of oral leukoplakia with photodynamic therapy: A pilot study

Abstract

There was satisfactory reduction in the size of the OL lesion without any side-effects. Thus, ALA mediated PDT seems to be a promising alternative for the treatment of OL.

Photodynamic treatment outcomes of potentially‐malignant lesions and malignancies of the head and neck region: A systematic review

“…The selected studies were clinical and had a prospective design with a range between two and 147 individuals (Tables and ) . Twelve studies reported a mean age of study participants of between 50 and 67 years (age range: 27‐99 years) .…”

“…In some of the studies, oral PMDS were OL, OE, OEL, OVH, OSMF, and OLP, in which PDT treatment has been undertaken . The total number of premalignant lesions reported in these studies was 815, with a range between five and 225 lesions . Twelve studies reported 465 patients with malignant lesions of the head and neck region who were underwent PDT treatment .…”

“…Twelve studies reported 465 patients with malignant lesions of the head and neck region who were underwent PDT treatment . Twenty‐five studies reported the site of lesions, which included buccal and labial mucosa (maxilla and mandible), tongue, palate, floor of the mouth, buccogingival sulcus, retromolar area, gingiva, and upper and lower alveolus for premalignant lesions, and palate, tongue, alveolus, retromolar area, floor of mouth, buccal mucosa, gingiva, pharynx and larynx, face, neck, maxillary sinus, oropharynx, nasopharynx, parotid gland, tonsil and nose for malignant lesions of the head and neck region . In nine studies, cancer was T 1 stage, whereas in five studies, cancer was T 2 stage .…”

“…All but one of the included studies used PDT as the sole treatment protocol for all the PMDS and HNSCC . The study that did not use PDT as the sole treatment protocol was that of Kawczyk‐Krupka et al., who compared the therapeutic potency of PDT with cryosurgery in patients with OL.…”

Oral Leukoplakia

“…The aim of the study is to treat patients with OL using PDT in which 5-aminolevulinic acid (ALA) is used as a photosensitizer. Selvam NP, Sadaksharam J, Singaravelu G, Ramu R. [7] were included five patients with OL. They were treated with 10% ALA mediated PDT (light source: Xenon lamp, power: 0.1 W, wavelength: 630 ± 5 nm, total dose: 100 J/cm 2 per session) for 6-8 sessions.…”